Breast Cancer CAR-T Cell Therapy

Introduction of CAR-T Cell Therapy

Chimeric antigen receptor T-cell immunotherapy (CAR-T) is a new type of precisely targeted therapy for tumor treatment, combining gene therapy and cell therapy technologies. In recent years, it has achieved good results in clinical tumor treatment through optimization and improvement. It is a promising new tumor immunotherapy method that can be accurate, fast, efficient, and may cure cancer. Breast cancer (BC) is one of the most frequently diagnosed malignancies and accounts for a large proportion of all cancer-related deaths in human females. CAR-T cell therapy is an innovative and effective immunotherapy for BC.

• HER2 is overexpressed in 20%-30% of BC, affecting the recurrence rate and ultimate survival rate. Co-expressing HER2- and MUC-1-specific CAR-T cells effectively killed BC cells that normally express both targets.
• The CSPG4 tumor glycoprotein was detected in TNBC stem cells, a major cause of relapse and drug resistance in this BC. CSPG4-CAR-T cells in TNBC can counteract this mechanism by downregulating CSPG4, thereby impairing metastasis and preventing BC progression.

Fig. 1. Production process of CAR-T cells. (Geng P, et al., 2023)

Breast Cancer CAR-T Cell Therapy Development Services

Alfa Cytology can provide you with BC CAR-T cell immunotherapy development services. The production process of CAR-T cells includes the enrichment and isolation of T cells, the preparation of CAR-T cells, the activation and expansion of T cells in vitro, the transduction of CAR genes, the expansion of CAR-T cells, etc. Our services include:

• Autologous CAR-T cells

The leukocytes of BC patients are separated, T cells are collected from peripheral blood, and then chimeric antigen receptors expressing specific tumor antigens are customized according to the specific conditions of BC patients.

• Allogeneic CAR-T cells

Allogeneic CAR-T cells refer to CAR-T cells from healthy donors. The T cells currently used for CAR-T cell production are mainly derived from peripheral blood mononuclear cells, but can also be derived from regenerative stem cells, such as induced pluripotent stem cells or embryonic stem cells. Compared with Autologous CAR-T cells, Allogeneic CAR-T cells have the advantages of low cost, ready-to-use, product standardization, and multi-cell modification.

Advantages of Our Services

• Professional CAR-T cell production platform
• Customized perfect solution
• Strict quality control
• High-quality team with rich experience

Alfa Cytology has CAR-T full-process solutions and is a full-process partner in the development of cellular immunotherapy. Our team is composed of highly educated and high-quality professionals with good professional backgrounds and experience in BC research. We have a complete set of technologies for CAR-T therapy development. If you are interested in learning more about our BC therapy development services, please feel free to contact us. Our professional and patient staff will contact you as soon as possible.